How Hybrid Closed-Loop Systems Help Level the Playing Field for Kids With Type 1 Diabetes
New Canadian research shows that advanced insulin pump technology may help reduce health disparities caused by social and economic challenges. The study suggests that access to these systems matters most for families facing housing instability and other hardships.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Hybrid closed-loop systems mediated—or reduced—the gap in blood sugar control between children in the most and least deprived neighborhoods
- The benefit was strongest for kids facing residential instability and situational vulnerability, two key social determinants of health
- About 46% of the children studied used hybrid closed-loop systems, while 54% used traditional injections or stand-alone pumps
- Economic factors alone did not show the same mediation effect, suggesting the technology's impact on disparities is complex
What the Research Asked
Social determinants of health—factors like housing stability, neighborhood resources, and economic security—significantly influence diabetes outcomes. Children living with Type 1 diabetes who face these challenges often struggle to achieve good blood sugar control, even as technology advances. Researchers at the Children's Hospital of Eastern Ontario wanted to know: does hybrid closed-loop (HCL) technology help narrow this gap?
The team reviewed medical records for 581 children with Type 1 diabetes seen at their clinic between May 2023 and May 2024. They measured social deprivation using postal codes and the Canadian Index of Multiple Deprivation, ranking neighborhoods from least to most deprived. They then looked at whether HCL use affected the relationship between deprivation and blood sugar outcomes.
What They Found
Among the 581 children studied (average age 13.4 years, mean disease duration 6.1 years), 46% used hybrid closed-loop systems while 54% used older technology: injections or stand-alone pumps. The average hemoglobin A1c was 8.0%.
Children in the most deprived neighborhoods typically had higher HbA1c levels than those in the least deprived areas—a familiar pattern in diabetes care. However, HCL system use significantly reduced this gap. The mediation effect was strongest for two factors: residential instability and situational vulnerability (conditions like food insecurity or frequent moves). For these children, HCL technology appeared to help compensate for the stress and practical barriers they faced.
Interestingly, economic dependency alone did not show the same mediation effect. This suggests that the technology's benefit is not simply about income, but rather about how it helps during specific hardships like housing instability.
What This Means
This research adds evidence that hybrid closed-loop systems do more than improve blood sugar control in general—they may actively help reduce health inequities. For children navigating housing instability or other forms of vulnerability, the automatic insulin delivery and reduced management burden of HCL systems appear particularly valuable.
However, the study also highlights an access question: not all children in the clinic had HCL systems. Ensuring equitable access to this technology, especially for families facing the greatest social and economic challenges, remains an important public health goal.
Looking Forward
This Canadian study offers a snapshot of one clinic's population and cannot be applied to all communities or regions. But it suggests that technology policy and insurance decisions should consider not just clinical benefits, but also the potential to reduce disparities. Future research in diverse populations would help confirm whether this pattern holds more broadly and what other supports families need alongside technology access.
Evidence label
Source: Hormone research in paediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Our own writing on the same ground.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryLiving With T1DWhat We're Learning About Diabetic Ketoacidosis in Type 1 Diabetes: A French StudyPubMed indexed literature
- Research summaryLiving With T1DCorrection to "The Use of an Automated Insulin Delivery System Is Associated With a Reduction in Diabetes Distress and Improvement in Quality of Life in People With Type 1 Diabetes".PubMed indexed literature
- Research summaryLiving With T1DA New Class of Biologics Could Change How We Treat Type 1 DiabetesPubMed indexed literature
- Research summaryLiving With T1DMenopause and Type 1 Diabetes: What Women Need to KnowPubMed indexed literature
- Research summaryLiving With T1DThe Promise and Challenge of Oral Insulin: Where the Research StandsPubMed indexed literature
- Research summaryLiving With T1DYour Glucose Range May Not Be the Guideline Range—And That's Worth UnderstandingPubMed indexed literature